Bovenkamp, v.d., Nassiri, Man, d., Oosterveer, Mourmans, Raalte, v., Dijkmans, Heerebeek, v., Empel, v., Eringa, Bakermans, & Handoko (2026). Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial.. European journal of heart failure.
Bovenkamp vd, Nassiri, Man d, Oosterveer, Mourmans, Raalte v, et al. Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial.. European journal of heart failure. 2026; PMID: 42148667
Bovenkamp vd, Nassiri, Man d, et al. Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial.[J]. European journal of heart failure. 2026.
@article{bovenkamp2026,
author = {van de Bovenkamp and Nassiri and de Man and Oosterveer and Mourmans and van Raalte and Dijkmans and van Heerebeek and van Empel and Eringa and Bakermans and Handoko},
title = {Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial.},
journal = {European journal of heart failure},
year = {2026},
note = {PMID: 42148667},
}
TY - JOUR AU - van de Bovenkamp AU - Nassiri AU - de Man AU - Oosterveer AU - Mourmans AU - van Raalte AU - Dijkmans AU - van Heerebeek AU - van Empel AU - Eringa AU - Bakermans AU - Handoko TI - Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial. T2 - European journal of heart failure PY - 2026 AN - PMID:42148667 ER -
Iron deficiency (ID) is common in patients with heart failure with preserved ejection fraction (HFpEF). The IRON-HFpEF trial aimed to evaluate the mechanistic effects of intravenous iron supplementation on cardiovascular function and exercise tolerance in HFpEF.